H. J. Graor

This study shows that targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer by disrupting redox balance and increasing ROS-induced apoptosis.

The paper provides detailed surgical techniques for orthotopic and splenic injections in a murine model of pancreatic cancer to improve preclinical research accuracy.

This study shows that inhibiting wild-type IDH1 enhances chemotherapy response in melanoma by reducing redox homeostasis and increasing reactive oxygen species.

This study shows that high glucose levels increase the effectiveness of chemotherapy in pancreatic cancer by reducing glutathione biosynthesis, which enhances oxidative stress in cancer cells.

This study shows that wild-type IDH1 is a metabolic target in pancreatic cancer cells under nutrient limitation, and FDA-approved drugs can inhibit it effectively in preclinical models.